These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 9154074)
1. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed). Cunningham D Tumori; 1997; 83(1 Suppl):S70-1. PubMed ID: 9154074 [No Abstract] [Full Text] [Related]
2. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Cunningham D Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851 [TBL] [Abstract][Full Text] [Related]
3. Results of a European multicentre trial of Tomudex versus 5-FU/high dose LV (Machover regimen). Cocconi G Tumori; 1997; 83(1 Suppl):S72. PubMed ID: 9154075 [No Abstract] [Full Text] [Related]
4. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Blackledge G Br J Cancer; 1998; 77 Suppl 2(Suppl 2):29-37. PubMed ID: 9579853 [TBL] [Abstract][Full Text] [Related]
5. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748 [No Abstract] [Full Text] [Related]
6. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562 [TBL] [Abstract][Full Text] [Related]
7. [Raltitrexed in colorectal cancer]. Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026 [No Abstract] [Full Text] [Related]
8. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Cunningham D; Zalcberg J; Smith I; Gore M; Pazdur R; Burris H; Meropol NJ; Kennealey G; Seymour L Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175 [TBL] [Abstract][Full Text] [Related]
9. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908 [TBL] [Abstract][Full Text] [Related]
10. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Gunasekara NS; Faulds D Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547 [TBL] [Abstract][Full Text] [Related]
11. Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Anderson H; Palmer MK Br J Cancer; 1998; 77 Suppl 2(Suppl 2):9-14. PubMed ID: 9579850 [TBL] [Abstract][Full Text] [Related]
12. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia. Nutting C; Folkes A Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593 [No Abstract] [Full Text] [Related]
13. Future developments with 'Tomudex' (raltitrexed). Van Cutsem E Anticancer Drugs; 1997 Aug; 8 Suppl 2():S33-8. PubMed ID: 9376636 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group. Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Kerr DJ Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632 [TBL] [Abstract][Full Text] [Related]
16. The potential role of Tomudex in the treatment of advanced colorectal cancer. Sobrero AF Tumori; 1997; 83(2):576-80. PubMed ID: 9226024 [TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer--is there an alternative to 5-FU? Bleiberg H Eur J Cancer; 1997 Apr; 33(4):536-41. PubMed ID: 9274432 [No Abstract] [Full Text] [Related]
18. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Kempin S; Gutierrez J; Wilson E; Lowery C; Diasio R Cancer Invest; 2002; 20(7-8):992-5. PubMed ID: 12449732 [TBL] [Abstract][Full Text] [Related]
19. Raltitrexed: current clinical status and future directions. Van Cutsem E; Cunningham D; Maroun J; Cervantes A; Glimelius B Ann Oncol; 2002 Apr; 13(4):513-22. PubMed ID: 12056700 [TBL] [Abstract][Full Text] [Related]
20. Drug resistance in colon cancer. Gorlick R; Bertino JR Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]